Genentech BFIRST

This is a Phase II, open-label, prospective, multicenter study designed to evaluate the efficacy and safety of single-agent atezolizumab in participants with treatment-naive locally advanced or metastatic NSCLC. In addition, the primary biomarker objective is to evaluate various predictive cutoffs for novel blood-based diagnostic assays.

See detailed information including eligibility.

Cancer, Adult Lung Cancer